Literature DB >> 22156560

Cancer dormancy: a model of early dissemination and late cancer recurrence.

David Páez1, Melissa J Labonte, Pierre Bohanes, Wu Zhang, Leonor Benhanim, Yan Ning, Takeru Wakatsuki, Fotios Loupakis, Heinz-Josef Lenz.   

Abstract

Cancer dormancy is a stage in tumor progression in which residual disease remains occult and asymptomatic for a prolonged period of time. Dormant tumor cells can be present as one of the earliest stages in tumor development, as well as a stage in micrometastases, and/or minimal residual disease left after an apparently successful treatment of the primary tumor. The general mechanisms that regulate the transition of disseminated tumor cells that have lain dormant into a proliferative state remain largely unknown. However, regulation of the growth from dormant tumor cells may be explained in part through the interaction of the tumor cell with its microenvironment, limitations in the blood supply, or an active immune system. An understanding of the regulatory machinery of these processes is essential for identifying early cancer biomarkers and could provide a rationale for the development of novel agents to target dormant tumor cells. This review focuses on the different signaling models responsible for early cancer dissemination and tumor recurrence that are involved in dormancy pathways.

Entities:  

Mesh:

Year:  2011        PMID: 22156560     DOI: 10.1158/1078-0432.CCR-11-2186

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  66 in total

1.  Genetic heterogeneity of circulating cells from patients with lymphangioleiomyomatosis with and without lung transplantation.

Authors:  Wendy K Steagall; Li Zhang; Xiong Cai; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2015-04-01       Impact factor: 21.405

2.  Dynamics of the cell-mediated immune response to tumour growth.

Authors:  Álvaro G López; Jesús M Seoane; Miguel A F Sanjuán
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2017-06-28       Impact factor: 4.226

Review 3.  Translating metastasis-related biomarkers to the clinic--progress and pitfalls.

Authors:  François-Clément Bidard; Jean-Yves Pierga; Jean-Charles Soria; Jean Paul Thiery
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

4.  Metastasis and the evolution of dispersal.

Authors:  Tazzio Tissot; François Massol; Beata Ujvari; Catherine Alix-Panabieres; Nicolas Loeuille; Frédéric Thomas
Journal:  Proc Biol Sci       Date:  2019-11-27       Impact factor: 5.349

5.  CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.

Authors:  Alex D Michaels; Timothy E Newhook; Sara J Adair; Sho Morioka; Bernadette J Goudreau; Sarbajeet Nagdas; Matthew G Mullen; Jesse B Persily; Timothy N J Bullock; Craig L Slingluff; Kodi S Ravichandran; J Thomas Parsons; Todd W Bauer
Journal:  Clin Cancer Res       Date:  2017-12-29       Impact factor: 12.531

Review 6.  The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.

Authors:  Sunao Shoji; Mayura Nakano; Haruhiro Sato; Xian Yang Tang; Yoshiyuki Robert Osamura; Toshiro Terachi; Toyoaki Uchida; Koichi Takeya
Journal:  Clin Exp Metastasis       Date:  2014-01       Impact factor: 5.150

7.  Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations.

Authors:  Nathalie Magnus; Delphine Garnier; Brian Meehan; Serge McGraw; Tae Hoon Lee; Maxime Caron; Guillaume Bourque; Chloe Milsom; Nada Jabado; Jacquetta Trasler; Rafal Pawlinski; Nigel Mackman; Janusz Rak
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

8.  Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.

Authors:  P Bohanes; D Yang; F Loupakis; M J LaBonte; A Gerger; Y Ning; C Lenz; F Lenz; T Wakatsuki; W Zhang; L Benhaim; A El-Khoueiry; R El-Khoueiry; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2014-12-09       Impact factor: 3.550

9.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

10.  The Mammary Tumor Microenvironment.

Authors:  Colleen S Curran; Suzanne M Ponik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.